Fulgent Genetics (FLGT) Depreciation & Amortization (CF) (2015 - 2026)

Fulgent Genetics has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $7.7 million in Q2 2026.

• Quarterly Depreciation & Amortization (CF) rose 26.79% year-over-year to $7.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $25.8 million (up 7.23% YoY) and the FY2025 annual result came in at $24.1 million, down 3.23% from the prior year.
• Depreciation & Amortization (CF) advanced to $7.7 million in Q2 2026 per FLGT's latest filing, from $6.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $9.8 million in Q3 2022 and troughed at $4.7 million in Q1 2022.
• A 5-year average of $6.8 million and a median of $6.3 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) jumped 245.12% in 2022, then slumped 34.63% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $9.8 million in 2022, then tumbled by 33.35% to $6.5 million in 2023, then decreased by 5.22% to $6.2 million in 2024, then dropped by 1.29% to $6.1 million in 2025, then increased by 25.59% to $7.7 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $7.7 million, $6.0 million, and $6.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.